JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Kodu・Aktsiate loetelu・Heron Therapeutics Inc

Heron Therapeutics Inc

Suletud

SektorTervishoid

1.22

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.19

Max

1.22

Põhinäitajad
By Trading Economics
Sissetulek	15M -3M
Müük	2.4M 41M
Aktsiakasum	-0.02
Kasumimarginaal	-7.278
Töötajad	128
EBITDA	13M -792K

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+268.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. mai 2026

Turustatistika
By TradingEconomics
Turukapital	6.2M 224M
Eelmine avamishind	1.22
Eelmine sulgemishind	1.22

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

2.0001 / 2.42 Toetus ja vastupanu

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. mai 2026, 23:43 UTC

Uudisväärsed sündmused

New Zealand's Unemployment Rate Falls in 1Q

5. mai 2026, 23:20 UTC

Kuumad aktsiad

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

5. mai 2026, 21:48 UTC

Tulu

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

5. mai 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

6. mai 2026, 00:00 UTC

Market Talk

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

5. mai 2026, 23:39 UTC

Market Talk

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

5. mai 2026, 22:26 UTC

Market Talk

AMD Data-Center Business Continues to Surge -- Market Talk

5. mai 2026, 22:20 UTC

Market Talk

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

5. mai 2026, 22:08 UTC

Tulu

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

5. mai 2026, 22:07 UTC

Tulu

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Adj EPS $1.09 >PAAS

5. mai 2026, 21:48 UTC

Tulu

Pan American Silver 1Q Rev $1.2B >PAAS

5. mai 2026, 21:42 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:38 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:30 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:29 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:26 UTC

Tulu

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q EPS 39c >ALC.EB

5. mai 2026, 21:25 UTC

Tulu

Alcon Inc. 1Q Rev $2.71B >ALC.EB

5. mai 2026, 21:24 UTC

Tulu

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

5. mai 2026, 21:18 UTC

Tulu

Mistras Backs 2026 Rev $730M-$750M >MG

5. mai 2026, 21:17 UTC

Tulu

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

5. mai 2026, 21:15 UTC

Tulu

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

5. mai 2026, 21:12 UTC

Tulu

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

5. mai 2026, 21:11 UTC

Tulu

SSR Mining 1Q Rev $581.8M >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q Adj EPS $1.15 >SSRM

5. mai 2026, 21:10 UTC

Tulu

SSR Mining 1Q EPS $1.16 >SSRM

5. mai 2026, 21:08 UTC

Tulu

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

5. mai 2026, 21:01 UTC

Tulu

Intact Financial 1Q EPS C$4.12 >IFC.T

5. mai 2026, 21:01 UTC

Kuumad aktsiad

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

268.85% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD 268.85%

Kõrge 6 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Heron Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.